Home

Alex Zisson

CIK 1512058 · last filed 2021-09-13

Alex Zisson is a corporate insider who has filed 11 SEC Form 4 insider transactions across 3 companies since 2011. The most recent filing, for CRXTW, was dated Sep 13, 2021. Across all open-market trades the lifetime net is −$37.8M, making them a net seller over the disclosed history. 3 SEC filings were submitted jointly with JAMES E THOMAS.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

11

Lifetime Open-Market Net

-$37.77M

Filer Profile

Reported Address
45 SOUTH 7TH STREET
SUITE 3060
MINNEAPOLIS, MN 55402
Related Filers
JAMES E THOMAS — 3 joint filings, latest 2013-07-17
THOMAS MCNERNEY & PARTNERS LP — 3 joint filings, latest 2013-07-17
ERIC AGUIAR — 1 joint filings, latest 2013-07-17
Pratik Shah — 1 joint filings, latest 2013-07-17
TMP Associates II LP — 1 joint filings, latest 2014-09-09
TMP Nominee II, LLC — 1 joint filings, latest 2014-09-09
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Clarus Therapeutics Holdings, Inc. (CRXTW) Delisted Director 490,531 $0.01 $6.7K $0 1 2021-09-13
Auspex Pharmaceuticals, Inc. (ASPX) Delisted Director 0 — — -$37.77M 6 2015-05-06
Ocera Therapeutics, Inc. (TZYM) Delisted Director — — — $0 2 2012-08-09

Recent Filings

11 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-09-13 Clarus Therapeutics Holdings, Inc. (CRXTW) Delisted Grant (A) +5,692,381 $0 EDGAR
2015-05-06 Auspex Pharmaceuticals, Inc. (ASPX) Delisted U −4,835,731 $0 EDGAR
2015-01-30 Auspex Pharmaceuticals, Inc. (ASPX) Delisted Sell (S) −730,000 -$38.77M EDGAR
2015-01-12 Auspex Pharmaceuticals, Inc. (ASPX) Delisted Mixed +295,127 -$264 EDGAR
2014-10-14 Auspex Pharmaceuticals, Inc. (ASPX) Delisted Mixed +50,380 -$55 EDGAR
2014-09-19 Auspex Pharmaceuticals, Inc. (ASPX) Delisted Mixed +53,439 -$26 EDGAR
2014-02-12 Auspex Pharmaceuticals, Inc. (ASPX) Delisted Mixed +5,166,785 $1.00M EDGAR
2013-07-17 — Mixed +2,500,002 $15.00M
2013-06-04 — Grant (A) — $0
2012-08-09 Ocera Therapeutics, Inc. (TZYM) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 11
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.